Purpose: To evaluate the in vitro and in vivo activity of posaconazole (PSC) against Aspergillus terreus. Methods: An in vitro study was performed with 21 strains of A. terreus using microdilution and Neo Sensitabs® tablet diffusion methods. A murine model of disseminated infection was developed using 2 strains of A. terreus. In this model, the in vivo efficacy of PSC was studied at doses of 5, 10 and 20 mg/kg twice per day. Results: All the strains were susceptible to PSC, the results being similar for the two methods. PSC 20 mg/kg (BID), and in many cases, PSC 10 mg/kg (BID) significantly prolonged the survival of mice and reduced the fungal load in kidney, lung and brain. On the seventh day of treatment, the serum levels of galactomannan became negative. The PSC levels in serum and spleen at 4 days of treatment were higher than the MIC for the strain tested. Conclusions: PSC could be a promising alternative in the treatment of systemicinfections by A. terreus.
Full conference title:
4th Advances Against Aspergillosis
- AAA 4th (2010)